Synthesis and antileishmanial activity of 3-(α-azolylbenzyl)indoles

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 17, Issue 6, 2002, Pages 353-358

  Marchand, Pascal ^a   Le Borgne, Marc ^a   Min Na, Young ^a   Pagniez, Fabrice ^a   Abdala, Hiam ^a   Le Baut, Guillaume ^a   Le Pape, Patrice ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Amastigotes; Antileishmanial agents; Azoles; Indoles; Promastigotes

Indexed keywords

3 (ALPHA AZOLYLBENZYL)INDOLE DERIVATIVE; 5 BROMO 1 ETHYL 3 [(2,4 DICHLOROPHENYL)(1H 1,2,4 TRIAZOL 1 YL)METHYL] 1H INDOLE; 5 BROMO 1 ETHYL 3 [(2,4 DICHLOROPHENYL)(1H IMIDAZOL 1 YL)METHYL] 1H INDOLE; ANTILEISHMANIAL AGENT; INDOLE DERIVATIVE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; PENTAMIDINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; FRIEDEL CRAFTS REACTION; IC 50; IN VITRO STUDY; LEISHMANIA MEXICANA; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

ACYLATION; ANIMALS; ANTIPROTOZOAL AGENTS; INDOLES; INHIBITORY CONCENTRATION 50; LEISHMANIA MEXICANA; STRUCTURE-ACTIVITY RELATIONSHIP;

LEISHMANIA MEXICANA; PROTOZOA;

EID: 0036954316     PISSN: 14756366     EISSN: None     Source Type: Journal    
DOI: 10.1080/1475636021000005613     Document Type: Article

References (23)

1. For information concerning leishmaniasis, please see the following worldwide web location: http//www.who.int/emc/diseases/leish/.
2. For information concerning Leishmania/HIV co-infection in southwestern Europe 1990-1998, please see the following worldwide web location: http://www.who.int/emc-documents/leishmaniasis/docs/wholeish200042.pdf.
3. Alvar, J., Canavate, C., Gutierrez-Solar, B., Jimenez, M., Laguna, F., Lopez-Velez, R., Molina, R. and Moreno, J. (1997) "Leishmania and human immunodeficiency virus coinfection: The first 10 years", Clinical Microbiology Reviews 10, 298-319.
4. Berman, J.D. (1997) "Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years", Clinical Infectious Diseases 24, 684-703.
5. Olliaro, P.L. and Bryceson, A.D.M. (1993) "Practical progress and new drugs for changing patterns of leishmaniasis", Parasitology Today 9, 323-328.
6. Ouellette, M. and Papadopoulou, B. (1993) "Mechanisms of drug resistance in Leishmania, Parasitology Today 9, 150-153.
7. United Nations Development Program/World Health Organization. Special Programme for Research and Training in Tropical Diseases (TDR) (1990) "Antimonials: Large-scale failure in leishmaniasis"alarming", TDR News 34, 7.
8. Yardley, V. and Croft, S.L. (2000) "A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis", International Journal of Antimicrobial Agents 13, 243-248.
9. Thakur, C.P. (2001) "A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): A pilot study", International Journal of Antimicrobial Agents 17, 67-70.
10. Murray, H.W. (2001) "Clinical and experimental advances in treatment of visceral leishmaniasis", Antimicrobial Agents and Chemotherapy 45, 2185-2197.
11. Berman, J.D., Goad, L.J., Beach, D.H. and Holz, Jr., G.G. (1986) "Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells", Molecular and Biochemical Parasitology 20, 85-92.
12. Dogra, J. and Saxena, V.N. (1996) "Itraconazole and leishmaniasis: A randomised double-blind trial in cutaneous disease", International Journal of Parasitology 26, 1413-1415.
13. Momeni, A.Z., Jalayer, T., Emamjomeh, M., Bashardost, N., Ghassemi, R.L., Meghdadi, M., Javadi, A. and Aminjavaheri, M. (1996) "Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study", Archives of Dermatology 132, 784-786.
14. Wali, J.P., Aggarwal, P., Gupta, U., Saluja, S. and Singh, S. (1992) "Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar", Journal of Infectious Diseases 166, 214-215.
15. Davidson, R.N. and Croft, S.L. (1993) "Recent advances in the treatment of visceral leishmaniasis", Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 130-131.
16. Rashid, J.R., Wasunna, K.M., Gachihi, G.S., Nyakundi, P.M., Mbugua, J. and Kirigi, G. (1994) "The efficacy and safety of ketoconazole in visceral leishmaniasis", East African Medicinal Journal 71, 392-395.
17. Al-Abdely, H.M., Graybill, J.R., Loebenberg, D. and Melby, P.C. (1999) "Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases", Antimicrobial Agents and Chemotherapy 43, 2910-2914.
18. Ketcha, D.M. and Gribble, G.W. (1985) "A convenient synthesis of 3-acylindoles via Friedel-Crafts acylation of 1-(phenylsulfonyl)indole. A new route to pyridocarbazole-5,11-quinones and Ellipticine", Journal of Organic Chemistry 50, 5451-5457.
19. Satoshi, O., Kozo, S., Natsuko, K., Yuki, S., Hirokazu, T., Masashi, H. (1991) "Indole derivatives". European Patent. 458,207.
20. Le Borgne, M., Na, Y.M., Pagniez, F., Abdala, H., Le Baut, G., Le Pape, P. (2000) "Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux dérivés de l'indole à titre de principes actifs d'une telle composition". French Patent 62937 L.
21. Berman, J.D. and Wyler, D. (1980) "An in vitro model for investigation of chemotherapeutic agents in leishmaniasis", Journal of Infectious Diseases 142, 83-86.
22. Katiyar, J.C., Anuradha and Sharma, S. (1992) "Kala-Azar: current status of experimental chemotherapy", Medicinal Research Reviews 12, 473-504.
23. Abdala, H., Robert, J-M., Le Pape, P., Wielgosz, G., Robert-Piessard, S. and Le Baut, G. (2000) "Synthesis and antileishmanial activity of new 1-(pyridin-2-yl)imidazolidin-2-ones derived from 2-amino-4,6-dimethylpyridine", Arzneimittel-Forschung/Drug Research 50(I), 479-484.